WEBULL

Lexaria FY26 nine-month net loss narrows to US$ 5.04 million; revenue drops to US$ 20,000

PUBT · 1d ago
Lexaria FY26 nine-month net loss narrows to US$ 5.04 million; revenue drops to US$ 20,000
  • Lexaria posted a net loss of US$ 5.04 million for the nine months ended May 31, 2026, narrowing from US$ 9.21 million a year earlier.
  • Revenue fell to US$ 20,000 from US$ 531,923, reflecting the expiration of the Premier Anti-Aging licensing contract.
  • Research and development expense dropped to US$ 2.12 million from US$ 6.36 million after completing its Phase 1b GLP-1-H24-4 clinical trial in December 2025.
  • Cash used in operating activities improved to US$ 4.78 million from US$ 7.81 million, while cash and cash equivalents totaled about US$ 3.5 million.
  • Lexaria expects cash resources to fund operations through the first quarter of fiscal 2027, while flagging substantial doubt about its ability to continue as a going concern.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-26-001166), on July 13, 2026, and is solely responsible for the information contained therein.